Given the initial clinical successes achieved using PD1/PDL1 or CTLA4 antibody treatments in patients with cancer, the number of immunotherapy agents in clinical development is expanding rapidly with goals of improving the limited response rate and generating more durable responses (48, 49). This evidence concerns the gene CD274 and cancer.